<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="119440">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02033070</url>
  </required_header>
  <id_info>
    <org_study_id>Barrett's RFA</org_study_id>
    <nct_id>NCT02033070</nct_id>
  </id_info>
  <brief_title>Patient Registry: Radio Frequency Ablation of Barrett's Esophagus Using HALO System</brief_title>
  <acronym>HALO</acronym>
  <official_title>Single Center Patient Registry Using Radio Frequency Ablation of Barrett's Esophagus Using HALO System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ochsner Health System</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ochsner Health System</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to provide a tool for physicians to compare outcome data
      related to the use of the HALO Ablation Systems.  This study is a single-center patient
      registry which will contribute to a framework for treatment and follow-up of patients with
      Barrett's  Esophagus.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2013</start_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <target_duration>2 Years</target_duration>
  <primary_outcome>
    <measure>Endoscopic clearance rate for Barrett's Esophagus</measure>
    <time_frame>Outcome measure is assessed at Month 12</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Histological clearance rate for intestinal metaplasia</measure>
    <time_frame>Biopsy taken at 12 months</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>Histological clearance rate for dysplasia</measure>
    <time_frame>Biopsy taken at 12 months to determine effectiveness</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <condition>Barrett's Esophagus</condition>
  <arm_group>
    <arm_group_label>Non-Dysplastic IM, LGD, HGD</arm_group_label>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum from Biopsy
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients presenting with esophageal intestinal metaplasia (IM), including  the
        pathological subclasses of non-dysplastic IM, low-grade dysplasia (LGD) and high-grade
        dysplasia (HGD)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  candidate for ablation of Barrett's Esophagus with the HALO Ablation System
             (Prospective)

          -  received an ablation with the HALO Ablation System to treat Barrett's Esophagus
             (Retrospective)

          -  candidate agrees to proposed follow-up schedule of yearly surveillance following
             treatment

          -  signs consent

        Exclusion Criteria:

          -  has not been diagnosed with Barrett's Esophagus
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Virendra Joshi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oshsner Clinic Foundation and Medical Center-Kenner</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ochsner Medical Center</name>
      <address>
        <city>Kenner</city>
        <state>Louisiana</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <lastchanged_date>January 9, 2014</lastchanged_date>
  <firstreceived_date>January 8, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ochsner Health System</investigator_affiliation>
    <investigator_full_name>Virendra Joshi</investigator_full_name>
    <investigator_title>Virendra Joshi, MD</investigator_title>
  </responsible_party>
  <keyword>RFA</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
